189 related articles for article (PubMed ID: 37465665)
1. Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.
Papaevangelou E; Esteves AM; Dasgupta P; Galustian C
Front Immunol; 2023; 14():1196829. PubMed ID: 37465665
[TBL] [Abstract][Full Text] [Related]
2. Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer.
Esteves AM; Papaevangelou E; Dasgupta P; Galustian C
Front Oncol; 2021; 11():621550. PubMed ID: 33777767
[TBL] [Abstract][Full Text] [Related]
3. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
[No Abstract] [Full Text] [Related]
4. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists.
Filderman JN; Taylor JL; Wang J; Zhang Y; Singh P; Ross MA; Watkins SC; Nedal Al Bzour A; Karapetyan L; Kalinski P; Storkus WJ
Front Immunol; 2024; 15():1334769. PubMed ID: 38312842
[TBL] [Abstract][Full Text] [Related]
5. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.
Berger G; Knelson EH; Jimenez-Macias JL; Nowicki MO; Han S; Panagioti E; Lizotte PH; Adu-Berchie K; Stafford A; Dimitrakakis N; Zhou L; Chiocca EA; Mooney DJ; Barbie DA; Lawler SE
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2111003119. PubMed ID: 35787058
[TBL] [Abstract][Full Text] [Related]
6. Targeting Prostate Cancer Using Intratumoral Cytotopically Modified Interleukin-15 Immunotherapy in a Syngeneic Murine Model.
Papaevangelou E; Smolarek D; Smith RA; Dasgupta P; Galustian C
Immunotargets Ther; 2020; 9():115-130. PubMed ID: 32802803
[TBL] [Abstract][Full Text] [Related]
7. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
[TBL] [Abstract][Full Text] [Related]
8. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.
Vonderhaar EP; Barnekow NS; McAllister D; McOlash L; Eid MA; Riese MJ; Tarakanova VL; Johnson BD; Dwinell MB
Cell Mol Gastroenterol Hepatol; 2021; 12(1):41-58. PubMed ID: 33548597
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model.
Zaidi AH; Kelly RJ; Gorbunova A; Omstead AN; Salvitti MS; Zheng P; Kosovec JE; Lee S; Ayazi S; Babar L; Finley GG; Goel A; Jobe BA
Oncotarget; 2021 Feb; 12(4):292-303. PubMed ID: 33659041
[TBL] [Abstract][Full Text] [Related]
10. Magnitude of Therapeutic STING Activation Determines CD8
Sivick KE; Desbien AL; Glickman LH; Reiner GL; Corrales L; Surh NH; Hudson TE; Vu UT; Francica BJ; Banda T; Katibah GE; Kanne DB; Leong JJ; Metchette K; Bruml JR; Ndubaku CO; McKenna JM; Feng Y; Zheng L; Bender SL; Cho CY; Leong ML; van Elsas A; Dubensky TW; McWhirter SM
Cell Rep; 2018 Dec; 25(11):3074-3085.e5. PubMed ID: 30540940
[TBL] [Abstract][Full Text] [Related]
11. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
[TBL] [Abstract][Full Text] [Related]
12. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
15. Selective STING stimulation in dendritic cells primes antitumor T cell responses.
Jneid B; Bochnakian A; Hoffmann C; Delisle F; Djacoto E; Sirven P; Denizeau J; Sedlik C; Gerber-Ferder Y; Fiore F; Akyol R; Brousse C; Kramer R; Walters I; Carlioz S; Salmon H; Malissen B; Dalod M; Piaggio E; Manel N
Sci Immunol; 2023 Jan; 8(79):eabn6612. PubMed ID: 36638189
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
17. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis.
Song C; Liu D; Liu S; Li D; Horecny I; Zhang X; Li P; Chen L; Miller M; Chowdhury R; Issa M; Shen R; Yan Y; Zhang F; Zhang L; Zhang L; Bai C; Feng J; Zhuang L; Zhang R; Li J; Wilkinson H; Liu J; Tao W
Sci Rep; 2022 May; 12(1):8579. PubMed ID: 35595822
[TBL] [Abstract][Full Text] [Related]
18. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
19. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.
Shi F; Su J; Wang J; Liu Z; Wang T
Mol Cell Biochem; 2021 Feb; 476(2):1015-1024. PubMed ID: 33141310
[TBL] [Abstract][Full Text] [Related]
20. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
